AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11887517 — intervention group
Group type: COMPARATOR
Intervention: Colgate Actibrush
Number of subjects: 59
Study 10442383 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy combined with pelvic radiation therapy
Number of subjects: 0
Study 10442383 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Number of subjects: 0
Study 7625793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 200 mg
Number of subjects: 16
Study 7625793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg
Number of subjects: 16
Study 7625793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 400 mg
Number of subjects: 16
Study 7625793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 600 mg
Number of subjects: 16
Study 7625793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir (all doses)
Number of subjects: 16
Study 7625793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir (200 to 400 mg administered twice daily)
Number of subjects: 16
Study 2653046 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids only (Group A)
Number of subjects: 57
Study 2653046 — intervention group
Group type: COMPARATOR
Intervention: Topical and systemic corticosteroids (Group B)
Number of subjects: 57
Study 2653046 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic cyclosporine with topical and systemic corticosteroids (Group C)
Number of subjects: 57
Study 333079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolmetin sodium
Number of subjects: 137
Study 333079 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 137
Study 31774581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (inOT)
Number of subjects: 31
Study 31774581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 31
Study 30706652 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 50 mg (I50)
Number of subjects: 15
Study 30706652 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg (D10)
Number of subjects: 15
Study 30706652 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride 100 mg (I100)
Number of subjects: 15
Study 30706652 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 15
Study 28508529 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice group
Number of subjects: 42
Study 28508529 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice group
Number of subjects: 42
Study 26422095 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg daily (<20 kg) or 10 or 20 mg daily (>20 kg) for 8 weeks
Number of subjects: 109
Study 26422095 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 109
Study 23427965 — intervention group
Group type: EXPERIMENTAL
Intervention: Celox
Number of subjects: 45
Study 23427965 — intervention group
Group type: EXPERIMENTAL
Intervention: ChitoGauze
Number of subjects: 45
Study 23427965 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Gauze
Number of subjects: 45
Study 23427965 — intervention group
Group type: EXPERIMENTAL
Intervention: HemCon wafer
Number of subjects: 45
Study 23427965 — intervention group
Group type: COMPARATOR
Intervention: Prior medical training
Number of subjects: 45
Study 21097785 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% micafungin (MCFG)
Number of subjects: 29
Study 21097785 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.2% fluconazole (FCZ)
Number of subjects: 29
Study 19052139 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 infusion (10 pmol/kg/min)
Number of subjects: 24
Study 19052139 — intervention group
Group type: EXPERIMENTAL
Intervention: PACAP38 infusion
Number of subjects: 24
Study 16696581 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem CR (12.5mg for younger adults, 6.25mg for elderly patients)
Number of subjects: 0
Study 16696581 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem CR
Number of subjects: 0
Study 16696581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15097955 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 436
Study 15097955 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 436
Study 11930695 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 100
Study 11930695 — intervention group
Group type: COMPARATOR
Intervention: TCu 380A
Number of subjects: 100
Study 9326194 — intervention group
Group type: EXPERIMENTAL
Intervention: mercaptopurine (lower doses)
Number of subjects: 740
Study 9326194 — intervention group
Group type: EXPERIMENTAL
Intervention: early intensification treatment
Number of subjects: 740
Study 9326194 — intervention group
Group type: EXPERIMENTAL
Intervention: myelosuppression during treatment
Number of subjects: 740
Study 8173926 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-contrast barium enema
Number of subjects: 462
Study 8173926 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 462
Study 8173926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (barium enema and flexible sigmoidoscopy)
Number of subjects: 462
Study 8173926 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium enema
Number of subjects: 462
Study 8173926 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic sigmoidoscopy before barium enema
Number of subjects: 462
Study 8173926 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 462
Study 2853091 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (A) 400 mg once-daily
Number of subjects: 12
Study 2853091 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E) 20 mg once-daily
Number of subjects: 12
Study 2853091 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Acebutolol and Enalapril (A + E)
Number of subjects: 12
Study 29880292 — intervention group
Group type: EXPERIMENTAL
Intervention: ABP 980
Number of subjects: 725
Study 29880292 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 725
Study 29880292 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab to ABP 980
Number of subjects: 725
Study 28070747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuedexta (dextromethorphan and quinidine)
Number of subjects: 60
Study 28070747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 25702144 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 63
Study 25702144 — intervention group
Group type: COMPARATOR
Intervention: Intensive nutritional care (INC)
Number of subjects: 63
Study 24200275 — intervention group
Group type: EXPERIMENTAL
Intervention: Myrin®-P Forte (FDC tablet containing rifampicin 150 mg, isoniazid 75 mg, ethambutol hydrochloride 275 mg, pyrazinamide 400 mg)
Number of subjects: 36
Study 24200275 — intervention group
Group type: COMPARATOR
Intervention: Individual products in loose combination (rifampicin, isoniazid, ethambutol hydrochloride, pyrazinamide)
Number of subjects: 36
Study 21169471 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled denufosol, 60 mg, three times daily (n = 178)
Number of subjects: 352
Study 21169471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 174)
Number of subjects: 352
Study 18658109 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam lysine (AZLI) 75 mg, twice or three times daily for 28 days
Number of subjects: 211
Study 18658109 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam lysine (AZLI) 75 mg
Number of subjects: 211
Study 18658109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 17196057 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day
Number of subjects: 46
Study 17196057 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 46
Study 17196057 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 46
Study 15490889 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reading intervention
Number of subjects: 0
Study 15490889 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal IQ, phonological skills, orthographic skills, rapid automatized naming (RAN), and attention ratings
Number of subjects: 0
Study 15490889 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal IQ-word reading discrepancy
Number of subjects: 0
Study 11092660 — intervention group
Group type: EXPERIMENTAL
Intervention: MIDCAB
Number of subjects: 0
Study 11092660 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 0
Study 8957034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ramipril (1.25 mg/d)
Number of subjects: 15
Study 8957034 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ramipril (5 mg/d)
Number of subjects: 15
Study 8957034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1550063 — intervention group
Group type: EXPERIMENTAL
Intervention: 1758 kJ/d (420 kcal/d)
Number of subjects: 76
Study 1550063 — intervention group
Group type: EXPERIMENTAL
Intervention: 2763 kJ/d (660 kcal/d)
Number of subjects: 76
Study 1550063 — intervention group
Group type: EXPERIMENTAL
Intervention: 3349 kJ/d (800 kcal/d)
Number of subjects: 76
Study 2862800 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone plus neuroleptic
Number of subjects: 7
Study 2862800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30615491 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid taping
Number of subjects: 72
Study 30615491 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 72
Study 30615491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 30615491 — intervention group
Group type: COMPARATOR
Intervention: Control (no taping)
Number of subjects: 72
Study 30615491 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 72
Study 27164676 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic brain injury patients
Number of subjects: 60
Study 27164676 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 24059806 — intervention group
Group type: EXPERIMENTAL
Intervention: KC‐1317 (a symbiotic mixture containing Saccharomyces boulardii lysate)
Number of subjects: 0
Study 24059806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22446739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 2591
Study 22446739 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive counselling
Number of subjects: 2591
Study 22446739 — intervention group
Group type: COMPARATOR
Intervention: Standard support
Number of subjects: 2591
Study 22446739 — intervention group
Group type: COMPARATOR
Intervention: Standard support with nicotine replacement therapy
Number of subjects: 2591
Study 22446739 — intervention group
Group type: COMPARATOR
Intervention: No nicotine replacement therapy
Number of subjects: 2591
Study 20735791 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin (4 mg, twice daily for 4 weeks)
Number of subjects: 0
Study 20735791 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg, once daily for 4 weeks)
Number of subjects: 0
Study 20735791 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin (after crossover)
Number of subjects: 0
Study 20735791 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (after crossover)
Number of subjects: 0
Study 18597909 — intervention group
Group type: EXPERIMENTAL
Intervention: INION system
Number of subjects: 60
Study 18597909 — intervention group
Group type: COMPARATOR
Intervention: Titanium miniplates
Number of subjects: 60
Study 15702440 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH in combination with metformin (MGH)
Number of subjects: 14
Study 15702440 — intervention group
Group type: COMPARATOR
Intervention: Metformin + Placebo (MP)
Number of subjects: 14
Study 15702440 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 12541165 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg/die
Number of subjects: 60
Study 12541165 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 2 g/die
Number of subjects: 60
Study 10877410 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ultrasound (3D US)
Number of subjects: 20
Study 10877410 — intervention group
Group type: COMPARATOR
Intervention: Control group (TIPS without 3D US)
Number of subjects: 20
Study 8932974 — intervention group
Group type: EXPERIMENTAL
Intervention: BARI hotline for recruitment support
Number of subjects: 1332
Study 8932974 — intervention group
Group type: EXPERIMENTAL
Intervention: BARI hotline for patient randomization backup
Number of subjects: 1332
Study 8932974 — intervention group
Group type: EXPERIMENTAL
Intervention: BARI hotline for protocol clarification
Number of subjects: 1332
Study 1813436 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) at 3 mg/kg/day for 5 days
Number of subjects: 66
Study 1813436 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) at 5 mg/kg/day for 5 days
Number of subjects: 66
Study 1813436 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) at 7 mg/kg/day for 5 days
Number of subjects: 66
Study 1813436 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) at 3-5 mg/kg/day
Number of subjects: 66
Study 1813436 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 66
Study 6613913 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg daily dietary aluminum (test diet)
Number of subjects: 8
Study 6613913 — intervention group
Group type: COMPARATOR
Intervention: 5 mg daily dietary aluminum (control diet)
Number of subjects: 8
Study 31028327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer, atraumatic restorative treatment method (HVGIC/ART)
Number of subjects: 405
Study 31028327 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermo-cured HVGIC/ART
Number of subjects: 405
Study 31028327 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-carbomer
Number of subjects: 405
Study 31028327 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite
Number of subjects: 405
Study 31028327 — intervention group
Group type: COMPARATOR
Intervention: Micro-cavitated dentine carious lesions (baseline code 2)
Number of subjects: 405
Study 31028327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed over micro-cavitated dentine carious lesions
Number of subjects: 405
Study 31028327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed over dentine lesions with a small orifice (Ø <0.5 mm)
Number of subjects: 405
Study 28655834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13130
Study 28655834 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13130
Study 25351652 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-based TLC diet (substituting two servings of red meat with legumes, 3 days per week)
Number of subjects: 31
Study 25351652 — intervention group
Group type: COMPARATOR
Intervention: Legume-free TLC diet
Number of subjects: 31
Study 25351652 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-based TLC diet
Number of subjects: 31
Study 23669281 — intervention group
Group type: EXPERIMENTAL
Intervention: YIC (HBsAg-HBIG immunogenic complex therapeutic vaccine)
Number of subjects: 450
Study 23669281 — intervention group
Group type: COMPARATOR
Intervention: Alum (placebo)
Number of subjects: 450
Study 23669281 — intervention group
Group type: EXPERIMENTAL
Intervention: YIC
Number of subjects: 450
Study 23669281 — intervention group
Group type: COMPARATOR
Intervention: Alum
Number of subjects: 450
Study 21616200 — intervention group
Group type: EXPERIMENTAL
Intervention: δ¹³C value of fingerstick blood
Number of subjects: 60
Study 21616200 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of added-sugar intake
Number of subjects: 60
Study 21616200 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean added-sugar consumption
Number of subjects: 60
Study 21616200 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean sugar-sweetened beverage consumption
Number of subjects: 60
Study 19176737 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with high-dose iron-folic acid for 90 days and single-dose (500 mg) mebendazole
Number of subjects: 6288
Study 19176737 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced treatment with 100 mg mebendazole twice daily for 3 days
Number of subjects: 6288
Study 19176737 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 days of daily multivitamins
Number of subjects: 6288
Study 19176737 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enhanced mebendazole and multivitamins
Number of subjects: 6288
Study 17971666 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg GGA t.i.d. for 2 weeks
Number of subjects: 128
Study 17971666 — intervention group
Group type: COMPARATOR
Intervention: 400 mg CIT b.i.d. for 2 weeks
Number of subjects: 128
Study 15600244 — intervention group
Group type: EXPERIMENTAL
Intervention: Antifungal agents
Number of subjects: 0
Study 15153583 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional foot orthoses
Number of subjects: 48
Study 15153583 — intervention group
Group type: COMPARATOR
Intervention: Accommodative foot orthoses
Number of subjects: 48
Study 10734666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.22 ppm for four hours with exercise)
Number of subjects: 27
Study 7627383 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg injected subcutaneously three times a day)
Number of subjects: 38
Study 7627383 — intervention group
Group type: COMPARATOR
Intervention: Control (conservative treatment alone)
Number of subjects: 38
Study 1790735 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponalrestat (600 mg daily)
Number of subjects: 30
Study 1790735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7041934 — intervention group
Group type: EXPERIMENTAL
Intervention: ibopamine (SB 7505, a new oral dopaminergic drug)
Number of subjects: 30
Study 7041934 — intervention group
Group type: EXPERIMENTAL
Intervention: frusemide
Number of subjects: 30
Study 7041934 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 30426166 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon high-intensity interval training (HIIT)
Number of subjects: 11
Study 30426166 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning high-intensity interval training (HIIT)
Number of subjects: 11
Study 28796888 — intervention group
Group type: EXPERIMENTAL
Intervention: full-mouth disinfection (FDIS) + MTZ
Number of subjects: 184
Study 28796888 — intervention group
Group type: COMPARATOR
Intervention: full-mouth disinfection (FDIS) + placebo
Number of subjects: 184
Study 28796888 — intervention group
Group type: EXPERIMENTAL
Intervention: scaling and root planing + MTZ
Number of subjects: 184
Study 28796888 — intervention group
Group type: COMPARATOR
Intervention: scaling and root planing + placebo
Number of subjects: 184
Study 26928164 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipital inhibitory pressure
Number of subjects: 76
Study 26928164 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipital spinal manipulation
Number of subjects: 76
Study 26928164 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of suboccipital inhibitory pressure and spinal manipulation
Number of subjects: 76
Study 26928164 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study 24276907 — intervention group
Group type: EXPERIMENTAL
Intervention: Madres a Madres program (intervention group with 113 mother-child dyads)
Number of subjects: 194
Study 24276907 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition (control group with 81 mother-child dyads)
Number of subjects: 194
Study 21345928 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of four deciduous canines
Number of subjects: 73
Study 21345928 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extraction)
Number of subjects: 73
Study 19618661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine administration (n = 10)
Number of subjects: 21
Study 19618661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 21
Study 17479573 — intervention group
Group type: EXPERIMENTAL
Intervention: KR good (knowledge of results after good trials)
Number of subjects: 0
Study 17479573 — intervention group
Group type: COMPARATOR
Intervention: KR poor (knowledge of results after poor trials)
Number of subjects: 0
Study 15710814 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 80
Study 15710814 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 80
Study 15710814 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 80
Study 15710814 — intervention group
Group type: EXPERIMENTAL
Intervention: Unoprostone
Number of subjects: 80
Study 15710814 — intervention group
Group type: COMPARATOR
Intervention: Lubricant drops (Control)
Number of subjects: 80
Study 15002546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of a balanced mixture of essential and non-essential amino acids at a rate of 0.1 g/kg/hour for 3 hours.
Number of subjects: 0
Study 15002546 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory group (control)
Number of subjects: 0
Study 15002546 — intervention group
Group type: COMPARATOR
Intervention: Bed rest group
Number of subjects: 0
Study 9891949 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite baseball players
Number of subjects: 20
Study 9891949 — intervention group
Group type: COMPARATOR
Intervention: Healthy sedentary subjects
Number of subjects: 20
Study 9891949 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite baseball players and Healthy sedentary subjects
Number of subjects: 20
Study 7625114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of trivalent cold-adapted recombinant influenza virus vaccine containing type A (H1N1 and H3N2) and B viruses.
Number of subjects: 128
Study 7625114 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of trivalent cold-adapted recombinant influenza virus vaccine.
Number of subjects: 128